SIRPA and cancer: Additionally, the DSPE-PEG2000-Mal-RS17 peptide (RS17 peptide), a peptide with antitumor properties, targets CD47 in cancer cells, inhibits the CD47–signal regulatory protein alpha (SIRPα) signaling pathway, and increases macrophage engulfment [26].